Urachal carcinoma is a rare tumor, it represents about 0.5-1% of all bladder malignancies. In the majority of cases it is an adenocarcinoma. For the treatment it is recommended for resectable tumors, a partial cystectomy with resection of the urachal ligament, the bladder dome and umbilicus. There is no standard neoadjuvant or adjuvant treatment, and the combinations of 5-fluoruracil with cisplatin are active in metastatic stage. A higher risk of relapse after surgery has been observed in some situations: positive margins, lymph node involvement, involvement of the peritoneal surface, or in the case of the umbilicus was not resected en-bloc.

In general, metastatic renal cell carcinoma (mRCC) is managed with systemic treatments and cytoreductive nephrectomy is recommended only when it is feasible. Historically, systemic treatment of mRCC was limited to cytokine treatment with interferon (IFN) and interleukin (IL)-2, as chemotherapy was considered to be ineffective in these patients. Bevacizumab in combination with interferon alfa is approved for treatment-nave advanced renal cell carcinoma (RCC) in both the US and Europe. Its objective response rates is 30%. We report a case of a patient who presents a complete response after a nephrectomy and bevacizumab associated to interferon alpha.